Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2013

View Archived Issues

Researchers publish report on chemically attenuated low-dose parasite-containing antimalaria vaccine

New renin inhibitors for the treatment of hypertension revealed by Daiichi Sankyo

Researchers in Poland present new caspase-3 and -7 activators

Plasma markers correlate with obstructive sleep apnea syndrome severity

Champions Oncology and Teva sign drug development agreement

Tetraphase describes novel tetracycline antibacterials

Evotec AG and Harvard Stem Cell Institute form CureMN collaboration

Mount Sinai grants Plexcera license to develop rhAC-based treatments

Circassia reports phase II findings for house dust mite allergy treatment

GlaxoSmithKline receives FDA priority review for dabrafenib/trametinib sNDAs

FDA grants breakthrough therapy designation to ofatumumab for previously untreated CLL

EMA grants orphan drug status to GMI-1070 in sickle cell disease

Data from phase II study of brincidofovir for preventing adenovirus disease presented

Cubist Pharmaceuticals completes acquisition of Trius Therapeutics

Ganymed obtains CE Mark for Claudetect 18.2 test

Bullet Biotechnology updates on financing and product development

Taiho Pharmaceutical divulges new Aurora kinase A inhibitors

Regeneron describes human monoclonal IgG4 antibodies targeting big ET-1

FDA lifts clinical hold on Pluristem's study of PLX-PAD for intermittent claudication

Adaptive Biotechnologies receives SBIR grant

Arbor Pharmaceuticals to market and sell Edarbi and Edarbyclor in U.S.

Swissmedic accepts for review ceftobiprole MAA for pneumonia

Astellas Pharma reports discovery of dual 5-HT2B/5-HT7 receptor antagonists for IBS

Alemtuzumab approved for multiple sclerosis in the E.U.

Tolvaptan approved in Japan to treat fluid retention in patients with hepatic cirrhosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...